Who are Ustekinumab - Standard Dosage's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ustekinumab (90 mg), Ustekinumab - Half-Standard Dosage.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ustekinumab-standard-dosage.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ustekinumab - Standard Dosage — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ustekinumab - Standard Dosage (Ustekinumab - Standard Dosage) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-12/23 inhibitor. Area: Immunology.

phase 3 IL-12/23 inhibitor p40 subunit of IL-12 and IL-23 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Ustekinumab - Standard Dosage (Ustekinumab - Standard Dosage) — Humanitas Clinical and Research Center. Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ustekinumab - Standard Dosage TARGET	Ustekinumab - Standard Dosage	Humanitas Clinical and Research Center	phase 3	IL-12/23 inhibitor	p40 subunit of IL-12 and IL-23
Ustekinumab (90 mg)	Ustekinumab (90 mg)	Janssen Scientific Affairs, LLC	phase 3	IL-12/23 inhibitor	p40 subunit of IL-12 and IL-23
Ustekinumab - Half-Standard Dosage	Ustekinumab - Half-Standard Dosage	Janssen Research & Development, LLC	phase 3	IL-12/23 inhibitor	p40 subunit of IL-12 and IL-23

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-12/23 inhibitor class)

Humanitas Clinical and Research Center · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Janssen Scientific Affairs, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ustekinumab - Standard Dosage — Competitive Intelligence Brief. https://druglandscape.com/ci/ustekinumab-standard-dosage. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab